Recombinant Human Disintegrin and metalloproteinase domain-containing protein 23 (ADAM23)

What is the standard methodology for generating cardiac-specific ADAM23 transgenic mouse models?

Cardiac-specific ADAM23 transgenic mice can be generated using a Cre-Lox conditional expression system. The methodology involves:

• Obtaining the full-length cDNA for mouse ADAM23 by polymerase chain reaction (PCR)

• Sequencing the cDNA to verify integrity

• Inserting the cDNA into a pCAG-loxP-CAT-loxp-lacZ plasmid by replacing the LacZ gene

• Generating the pCAG-CAT-mADAM23 plasmid containing the CAG promoter and LoxP-flanked CAT gene

• Linearizing the transgene vector and microinjecting it into fertilized murine embryos (C57BL/6J)

• Characterizing offspring genotypes via PCR on tail DNA samples

• Breeding CAG-CAT-mADAM23 mice with α-MHC-MerCreMer mice to generate double-transgenic mice

• Inducing Cre-mediated recombination with tamoxifen injection (25 mg/kg daily for five consecutive days)

This approach allows for temporal control of ADAM23 overexpression specifically in cardiomyocytes, enabling precise examination of its functional role in the heart.

How can researchers effectively create cardiac-specific ADAM23 knockout models?

Cardiac-specific ADAM23 knockout (cADAM23-KO) mice can be established using the CRISPR/Cas9 system through the following protocol:

• Clone the exon 3 coding sequence region of mouse ADAM23 gene and flank it with two mLoxP sequences

• Clone the recombinant DNA fragment into a vector containing homology arms (approximately 1153 and 1414 bp)

• Design two single-guide RNAs targeting locations in the CDS region using online tools (http://crispr.mit.edu/)

• Synthesize and validate sgRNAs for specificity and function in vitro

• Inject Cas9 mRNA, sgRNAs, and donor vector into C57BL/6J mouse zygotes

• Transplant injected zygotes into surrogate mother mice

• Identify founder mice with floxed CDS regions on the same allele

• Confirm floxed allele functionality through in vitro Cre/loxP-mediated recombination

• Breed with cardiac-specific Cre-expressing mice to generate tissue-specific knockouts

This approach provides a powerful tool to study the loss-of-function effects of ADAM23 specifically in cardiac tissue, eliminating potentially confounding developmental effects from global knockout.

What are the optimal methods for culturing and manipulating primary cardiomyocytes to study ADAM23 function?

The preparation and manipulation of neonatal rat cardiomyocytes (NRCMs) for ADAM23 studies follows these methodological steps:

• Harvest hearts from 1-day-old Sprague-Dawley rats

• Excise, mince, and digest the tissue with trypsin

• Pass digested tissue through a 40-μm cell strainer

• Use differential attachment technique to remove fibroblasts

• Seed cardiomyocytes in DMEM/F12 medium containing 20% fetal bovine serum, BrdU (to inhibit fibroblast proliferation), and antibiotics

• For knockdown experiments, clone rat shADAM23 constructs into adenoviral vectors (using non-targeting AdshRNA as control)

• For overexpression, subclone the entire coding region of rat ADAM23 gene under cytomegalovirus promoter control into adenoviral vectors (AdADAM23), using AdGFP as control

• Infect cultured NRCMs with respective adenoviral constructs at a multiplicity of infection of 100 for 24 hours

• Replace medium with DMEM/F12 containing 1% fetal bovine serum for 12 hours to synchronize cardiomyocytes

• Stimulate cells with angiotensin II (1 μmol/L) or PBS (control) for 48 hours

This protocol enables reliable in vitro analysis of ADAM23 function in cardiomyocytes and is suitable for assessing hypertrophic responses through immunofluorescence staining and gene expression analysis.

What techniques are recommended for producing and purifying the disintegrin-like domain of ADAM23?

For functional studies of the ADAM23 disintegrin-like domain, researchers can employ the following production and purification approach:

• Design and synthesize expression constructs containing the disintegrin-like domain sequence

• Express the recombinant protein in Escherichia coli expression systems

• Optimize expression conditions (temperature, induction time, and IPTG concentration)

• Lyse bacterial cells and solubilize the target protein

• Perform affinity chromatography using appropriate tags (e.g., His-tag) for initial purification

• Apply additional purification steps as needed (ion exchange, size exclusion chromatography)

• Verify purity by SDS-PAGE and Western blotting

• Confirm biological activity through cell adhesion assays

The purified disintegrin-like domain can then be immobilized on culture dishes to assess its ability to promote attachment of different human cells, particularly those of neural origin such as neuroblastoma cells (NB100, SH-SY5Y) or astrocytoma cells (U373, U87 MG).

What methods are most appropriate for analyzing ADAM23 expression in tissue samples?

Analysis of ADAM23 expression in tissue samples can be approached through multiple complementary techniques:

• RT-qPCR Analysis:

  • Extract total RNA from tissue samples using standard protocols

  • Perform reverse transcription to generate cDNA

  • Design specific primers for human or mouse ADAM23

  • Quantify expression levels relative to appropriate housekeeping genes

• Western Blot Analysis:

  • Extract proteins from tissue samples using appropriate lysis buffers

  • Separate proteins by SDS-PAGE and transfer to membranes

  • Probe with validated anti-ADAM23 antibodies

  • Visualize and quantify signals using appropriate detection systems

• Immunohistochemistry (IHC):

  • Prepare formalin-fixed paraffin-embedded (FFPE) tissue sections

  • Perform antigen retrieval if necessary

  • Incubate with primary anti-ADAM23 antibodies

  • Apply appropriate detection systems (e.g., HRP-conjugated secondary antibodies)

  • Analyze staining patterns and intensity

• Methylation Analysis (for epigenetic regulation):

  • Extract DNA from tissue samples

  • Perform bisulfite conversion of DNA

  • Analyze ADAM23 promoter methylation level by quantitative pyrosequencing

  • Design amplification primers for the region of interest

These complementary approaches provide comprehensive analysis of ADAM23 expression at mRNA, protein, and epigenetic regulation levels.

How can researchers comprehensively evaluate the role of ADAM23 in the FAK/AKT signaling pathway during cardiac hypertrophy?

To evaluate ADAM23's role in FAK/AKT signaling during cardiac hypertrophy, researchers should implement a multi-level experimental approach:

• In vivo signaling analysis:

  • Subject ADAM23 transgenic and knockout mice to pressure overload via aortic banding (AB)

  • Harvest cardiac tissue at defined timepoints post-surgery

  • Prepare protein lysates and perform Western blot analysis for:

    • Phosphorylated and total FAK

    • Phosphorylated and total AKT

    • Downstream molecules: GSK3β and mTOR (both phosphorylated and total forms)

  • Compare expression and activation patterns between experimental groups

• In vitro validation:

  • Manipulate ADAM23 expression in NRCMs using adenoviral vectors

  • Treat cells with hypertrophic stimuli (e.g., angiotensin II)

  • Analyze FAK/AKT pathway activation by Western blotting

  • Perform time-course experiments to determine signaling kinetics

• Pharmacological intervention:

  • Treat ADAM23-deficient mice with FAK inhibitors (e.g., PF-562271)

  • Evaluate the rescue of hypertrophic phenotypes through:

    • Heart weight/body weight ratios

    • Heart weight/tibia length ratios

    • Echocardiographic assessment

    • Histological analysis of cardiomyocyte size and fibrosis

  • Confirm pathway inhibition via Western blotting

This comprehensive approach allows for mechanistic understanding of how ADAM23 regulates cardiac hypertrophy through the FAK/AKT signaling pathway.

What experimental designs best elucidate ADAM23's interaction with integrin αvβ3?

The investigation of ADAM23-integrin αvβ3 interactions requires specialized experimental designs:

• Binding assays:

  • Express and purify the disintegrin-like domain of ADAM23

  • Immobilize the recombinant protein on plates or beads

  • Incubate with soluble purified integrins or cell lysates containing integrins

  • Detect interactions using specific antibodies

  • Perform competition assays with known integrin ligands to determine specificity

• Cell adhesion assays:

  • Coat culture dishes with recombinant ADAM23 disintegrin-like domain

  • Plate various cell types (particularly neuroblastoma and astrocytoma cells)

  • Quantify cell attachment and spreading

  • Perform inhibition studies using:

    • Anti-integrin blocking antibodies

    • Integrin-binding peptides

    • Soluble recombinant integrins

• Transfection studies:

  • Transfect cells (e.g., HeLa cells) with full-length ADAM23 cDNA

  • Assess adhesion properties of transfected cells

  • Analyze integrin dependency using function-blocking antibodies

  • Perform co-immunoprecipitation experiments to confirm physical interactions

• Peptide mapping:

  • Design synthetic peptides corresponding to putative binding sequences in the disintegrin loop

  • Test peptides in competition assays to identify the minimal binding motif

  • Create point mutations in the binding sequence to determine critical residues

  • Note that ADAM23's interaction with αvβ3 occurs despite lacking the RGD motif common in other disintegrins

These approaches collectively provide a comprehensive analysis of the ADAM23-integrin αvβ3 interaction mechanism.

What are the most robust methods for investigating ADAM23 promoter methylation patterns in tumor samples?

Investigation of ADAM23 promoter methylation in tumor samples requires specialized epigenetic analysis techniques:

• Bisulfite conversion and pyrosequencing:

  • Extract genomic DNA from fresh or formalin-fixed paraffin-embedded (FFPE) tumor tissues

  • Perform bisulfite conversion of DNA (converts unmethylated cytosines to uracils)

  • Design primers specific to the ADAM23 promoter region

  • Amplify the region of interest from bisulfite-modified DNA

  • Perform quantitative pyrosequencing to measure methylation levels at individual CpG sites

  • Calculate mean methylation levels across the analyzed region

• Methylation-specific PCR (MSP):

  • Design primer pairs specific for methylated and unmethylated sequences after bisulfite conversion

  • Perform PCR reactions with both primer sets

  • Analyze products by gel electrophoresis to determine methylation status

  • Include appropriate positive and negative controls

• Correlation with expression:

  • Perform immunohistochemistry (IHC) on the same tumor samples to detect ADAM23 protein expression

  • Identify representative tumor areas for analysis

  • Score expression levels semi-quantitatively

  • Correlate methylation levels with protein expression to establish functional significance

  • Analyze associations with clinical parameters (tumor stage, grade, patient survival)

• Functional validation:

  • Treat cell lines with demethylating agents (e.g., 5-aza-2'-deoxycytidine)

  • Assess changes in ADAM23 expression by RT-qPCR and Western blotting

  • Evaluate phenotypic consequences (proliferation, migration, invasion)

These methodologies provide comprehensive characterization of ADAM23 methylation patterns and their functional significance in tumor biology.

How can researchers accurately assess the cardiac phenotypes in ADAM23 transgenic and knockout mouse models?

Comprehensive assessment of cardiac phenotypes in ADAM23 mouse models requires a multi-parameter approach:

• Morphometric analysis:

  • Calculate heart weight/body weight (HW/BW) ratios

  • Determine heart weight/tibia length (HW/TL) ratios to normalize for potential differences in body size

  • Perform gross anatomical assessment of cardiac structures

• Echocardiographic evaluation:

  • Measure left ventricle end-diastolic dimension (LVEDd)

  • Calculate fractional shortening (FS) to assess contractile function

  • Evaluate wall thickness and mass

  • Perform tissue Doppler imaging for diastolic function assessment

• Histological analysis:

  • Prepare heart sections stained with:

    • Hematoxylin and eosin (H&E) for general morphology

    • Wheat germ agglutinin (WGA) for cardiomyocyte boundaries

    • Masson's trichrome or Sirius red for fibrosis

  • Measure cardiomyocyte cross-sectional area (CSA) from WGA-stained sections

  • Quantify perivascular and interstitial fibrosis area

• Molecular characterization:

  • Analyze mRNA levels of hypertrophy markers including:

    • Atrial natriuretic peptide (Anp)

    • Brain natriuretic peptide (Bnp)

    • β-myosin heavy chain (β-Mhc)

  • Evaluate fibrosis markers:

    • Collagen I and III

    • Connective tissue growth factor (Ctgf)

• Pressure overload response:

  • Subject mice to aortic banding (AB) surgery

  • Include appropriate sham-operated controls

  • Evaluate cardiac structure and function at defined timepoints (e.g., 4 weeks post-surgery)

  • Compare responses between genotypes

This comprehensive phenotyping approach provides robust assessment of ADAM23's role in cardiac pathophysiology.

What techniques are most effective for studying potential ADAM23-mediated cell adhesion in neurological disorders?

To investigate ADAM23-mediated cell adhesion in neurological contexts, researchers should employ these specialized techniques:

• Cell-matrix adhesion assays:

  • Coat surfaces with purified recombinant ADAM23 disintegrin domain

  • Plate neural cells (neuroblastoma lines NB100, SH-SY5Y or astrocytoma lines U373, U87 MG)

  • Quantify adhesion by colorimetric or fluorescence-based methods

  • Perform competitive inhibition studies with specific antibodies or peptides

• Integrin profiling:

  • Analyze integrin expression profiles of neural cells using flow cytometry

  • Focus particularly on αvβ3 integrin expression levels

  • Correlate expression with adhesion capability to ADAM23 substrates

  • Manipulate integrin expression levels and assess effects on ADAM23-mediated adhesion

• Co-culture experiments:

  • Generate stable cell lines expressing ADAM23

  • Co-culture with neural cells expressing appropriate integrins

  • Assess cell-cell interactions through microscopy and aggregation assays

  • Evaluate the role of ADAM23 in these interactions using function-blocking antibodies

• Ex vivo neural tissue studies:

  • Prepare brain slices from appropriate animal models

  • Apply recombinant ADAM23 or ADAM23-expressing cells

  • Analyze neural cell migration, adhesion, and neurite outgrowth

  • Compare responses between normal and disease models

• In vivo models of neurological disorders:

  • Generate conditional ADAM23 knockout or overexpression in specific neural cell populations

  • Assess pathological outcomes in models of neurological disorders

  • Evaluate whether ADAM23-mediated adhesion contributes to disease progression or protection

These approaches provide a comprehensive framework for investigating ADAM23's role in neural cell adhesion in normal physiology and neurological disease contexts.